210 related articles for article (PubMed ID: 37513921)
1. An Intriguing Purview on the Design of Macrocyclic Inhibitors for Unexplored Protein Kinases through Their Binding Site Comparison.
Bhujbal SP; Hah JM
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513921
[TBL] [Abstract][Full Text] [Related]
2. Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform.
Meng F; Liu J; Cao Z; Yu J; Steurer B; Yang Y; Wang Y; Cai X; Zhang M; Ren F; Aliper A; Ding X; Zhavoronkov A
Bioorg Chem; 2024 May; 146():107285. PubMed ID: 38547721
[TBL] [Abstract][Full Text] [Related]
3. Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle.
Zhang C; Liu F; Zhang Y; Song C
Eur J Med Chem; 2024 Mar; 268():116234. PubMed ID: 38401189
[TBL] [Abstract][Full Text] [Related]
4. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
5. Macrocycles in new drug discovery.
Mallinson J; Collins I
Future Med Chem; 2012 Jul; 4(11):1409-38. PubMed ID: 22857532
[TBL] [Abstract][Full Text] [Related]
6. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
7. Macrocyclization of linear molecules by deep learning to facilitate macrocyclic drug candidates discovery.
Diao Y; Liu D; Ge H; Zhang R; Jiang K; Bao R; Zhu X; Bi H; Liao W; Chen Z; Zhang K; Wang R; Zhu L; Zhao Z; Hu Q; Li H
Nat Commun; 2023 Jul; 14(1):4552. PubMed ID: 37507402
[TBL] [Abstract][Full Text] [Related]
8. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.
Lamba V; Ghosh I
Curr Pharm Des; 2012; 18(20):2936-45. PubMed ID: 22571662
[TBL] [Abstract][Full Text] [Related]
9. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
[TBL] [Abstract][Full Text] [Related]
10. TWN-RENCOD: A novel method for protein binding site comparison.
Choi KE; Balupuri A; Kang NS
Comput Struct Biotechnol J; 2023; 21():425-431. PubMed ID: 36618985
[TBL] [Abstract][Full Text] [Related]
11. Binding site matching in rational drug design: algorithms and applications.
Naderi M; Lemoine JM; Govindaraj RG; Kana OZ; Feinstein WP; Brylinski M
Brief Bioinform; 2019 Nov; 20(6):2167-2184. PubMed ID: 30169563
[TBL] [Abstract][Full Text] [Related]
12. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
13. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Macrocyclic mTOR Modulators of Rapamycin Binding Site via Pharmacoinformatics Approaches.
Parate S; Kumar V; Hong JC; Lee KW
Comput Biol Chem; 2023 Jun; 104():107875. PubMed ID: 37148678
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
[TBL] [Abstract][Full Text] [Related]
16. KiSSim: Predicting Off-Targets from Structural Similarities in the Kinome.
Sydow D; Aßmann E; Kooistra AJ; Rippmann F; Volkamer A
J Chem Inf Model; 2022 May; 62(10):2600-2616. PubMed ID: 35536589
[TBL] [Abstract][Full Text] [Related]
17. Computational studies of molecular pre-organization through macrocyclization: Conformational distribution analysis of closely related non-macrocyclic and macrocyclic analogs.
Olanders G; Brandt P; Sköld C; Karlén A
Bioorg Med Chem; 2021 Nov; 49():116399. PubMed ID: 34601455
[TBL] [Abstract][Full Text] [Related]
18. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches.
Gani OA; Thakkar B; Narayanan D; Alam KA; Kyomuhendo P; Rothweiler U; Tello-Franco V; Engh RA
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1605-16. PubMed ID: 26001898
[TBL] [Abstract][Full Text] [Related]
19. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.
Naumann T; Matter H
J Med Chem; 2002 Jun; 45(12):2366-78. PubMed ID: 12036347
[TBL] [Abstract][Full Text] [Related]
20. Accurate and Reliable Prediction of the Binding Affinities of Macrocycles to Their Protein Targets.
Yu HS; Deng Y; Wu Y; Sindhikara D; Rask AR; Kimura T; Abel R; Wang L
J Chem Theory Comput; 2017 Dec; 13(12):6290-6300. PubMed ID: 29120625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
